First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

528 Reviews

Credit Rating - OPTIPHARM PHARMACEUTICALS LIMITED

ANALYSIS
Credit Risk Update: SECURED CREDITOR INFORMATION: OPTIPHARM PHARMACEUTICALS LIMITED, 29 BRIDGE ROAD, WEMBLEY, MIDDLESEX, HA9 9AB. The legal status is a Private Limited Company and the current status at the registry of companies is Active. The last filed accounts are dated 31 December 2022. The company was incorporated on 26 October 2001.

The accounts next due date is 30 September 2024. There is 1 mortgage, which is unsatisfied

The above was based on public record information as at 8 January 2025 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 04311794
Date Incorporated: 26 October 2001
Date Latest Accounts: 31 December 2022
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: None
Registered Number: 04311794
Annual Return: 26 October 2015
Registered Office: 29 BRIDGE ROAD, WEMBLEY, MIDDLESEX, HA9 9AB
SIC Code and Operations: 47730
SECURED CREDITORS
Number of Mortgages 1
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 1
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

OPTIPHARM PHARMACEUTICALS LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 18 January 2025 Copyright © 2025 First Report Ltd


Recent Searches

Reg No. Reg Name Status
08948225 OPTI-PHARMA (UK) LIMITED Active
SC589137 OPTIPHOTON TECHNOLOGY LIMITED Active - Proposal to Strike off
13191818 OPTIPHY LIMITED Active
11465462 OPTIPIX LIMITED Active
14878895 OPTIPLACE LTD Active - Proposal to Strike off

In using this service you agree to the Terms and Conditions

© 2025 First Report Ltd